var data={"title":"Vancomycin: Parenteral dosing, monitoring, and adverse effects in adults","body":"<div id=\"topicContent\" class=\"utdArticleSection utdStyle\"><div id=\"topicTitle\">Vancomycin: Parenteral dosing, monitoring, and adverse effects in adults</div><dl id=\"topicContributors\"><dt><span> </span>Authors:</dt><dd><a href=\"https://www.uptodate.com/contents/vancomycin-parenteral-dosing-monitoring-and-adverse-effects-in-adults/contributors\" class=\"contributor contributor_credentials\">Richard H Drew, PharmD, MS, FCCP, FIDP</a></dd><dd><a href=\"https://www.uptodate.com/contents/vancomycin-parenteral-dosing-monitoring-and-adverse-effects-in-adults/contributors\" class=\"contributor contributor_credentials\">George Sakoulas, MD</a></dd><dt><span> </span>Section Editor:</dt><dd><a href=\"https://www.uptodate.com/contents/vancomycin-parenteral-dosing-monitoring-and-adverse-effects-in-adults/contributors\" class=\"contributor contributor_credentials\">David C Hooper, MD</a></dd><dt><span> </span>Deputy Editor:</dt><dd><a href=\"https://www.uptodate.com/contents/vancomycin-parenteral-dosing-monitoring-and-adverse-effects-in-adults/contributors\" class=\"contributor contributor_credentials\">Elinor L Baron, MD, DTMH</a></dd></dl><p class=\"disclosureLink\"><a href=\"https://www.uptodate.com/contents/vancomycin-parenteral-dosing-monitoring-and-adverse-effects-in-adults/contributor-disclosure\" class=\"contributor contributor_credentials\">Contributor Disclosures</a></p><div id=\"reviewProcess\"><span>All topics are updated as new evidence becomes available and our <a href=\"https://www.uptodate.com/home/editorial-policy\" target=\"_blank\" class=\"policy policy_editorialpolicy\">peer review process</a> is complete.</span></div><div id=\"literatureReviewDate\"><span class=\"emphasis\">Literature review current through:</span>&#160;Feb 2018.&#160;&#124;&#160;<span class=\"emphasis\">This topic last updated:</span>&#160;Dec 04, 2017.</div><div id=\"topicWhatsNewContainer\"></div><div id=\"topicText\"><p class=\"headingAnchor\" id=\"H1\"><span class=\"h1\">INTRODUCTION</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span><a href=\"topic.htm?path=vancomycin-drug-information\" class=\"drug drug_general\">Vancomycin</a> is a glycopeptide antibiotic used intravenously for treatment of patients with suspected or proven invasive gram-positive infections, including methicillin-resistant <em>Staphylococcus aureus </em>(MRSA).</p><p>Appropriate dosing and administration of <a href=\"topic.htm?path=vancomycin-drug-information\" class=\"drug drug_general\">vancomycin</a> requires consideration of the infection site, disease severity, patient weight, renal function, and pathogen susceptibility [<a href=\"https://www.uptodate.com/contents/vancomycin-parenteral-dosing-monitoring-and-adverse-effects-in-adults/abstract/1,2\" class=\"abstract_t\">1,2</a>]. Careful attention to individualizing therapy and use of serum concentration monitoring are important for optimizing vancomycin dosing [<a href=\"https://www.uptodate.com/contents/vancomycin-parenteral-dosing-monitoring-and-adverse-effects-in-adults/abstract/3-6\" class=\"abstract_t\">3-6</a>].</p><p>Issues related to <a href=\"topic.htm?path=vancomycin-drug-information\" class=\"drug drug_general\">vancomycin</a> dosing and serum concentration monitoring will be reviewed here. Issues related to vancomycin hypersensitivity are discussed separately. (See <a href=\"topic.htm?path=vancomycin-hypersensitivity\" class=\"medical medical_review\">&quot;Vancomycin hypersensitivity&quot;</a>.)</p><p class=\"headingAnchor\" id=\"H3529742722\"><span class=\"h1\">DOSING AND ADMINISTRATION</span></p><p class=\"headingAnchor\" id=\"H8\"><span class=\"h2\">Clinical approach</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>The clinical approach to <a href=\"topic.htm?path=vancomycin-drug-information\" class=\"drug drug_general\">vancomycin</a> dosing is based on the type and severity of infection, patient weight, and renal function [<a href=\"https://www.uptodate.com/contents/vancomycin-parenteral-dosing-monitoring-and-adverse-effects-in-adults/abstract/3-7\" class=\"abstract_t\">3-7</a>]:</p><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>For patients with deep-seated infection (including bacteremia, endocarditis, osteomyelitis, prosthetic joint infection, pneumonia warranting hospitalization, infection involving the central nervous system, <span class=\"nowrap\">and/or</span> critical illness), an initial <a href=\"topic.htm?path=vancomycin-drug-information\" class=\"drug drug_general\">vancomycin</a> loading dose (25 to 30 <span class=\"nowrap\">mg/kg,</span> rounded to the nearest 250 mg increment) may be administered. Thereafter, intermittent maintenance dosing should be administered to achieve a target serum trough concentration of 15 to 20 <span class=\"nowrap\">mcg/mL</span> [<a href=\"https://www.uptodate.com/contents/vancomycin-parenteral-dosing-monitoring-and-adverse-effects-in-adults/abstract/8,9\" class=\"abstract_t\">8,9</a>]. (See <a href=\"#H3722373455\" class=\"local\">'Loading dose'</a> below and <a href=\"#H3053721516\" class=\"local\">'Target concentrations'</a> below.)</p><p/><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>For patients with nonsevere infection (such as soft tissue infection), a loading <a href=\"topic.htm?path=vancomycin-drug-information\" class=\"drug drug_general\">vancomycin</a> dose is not necessary. Vancomycin should be administered intermittently to achieve a serum target trough concentration of 10 to 15 <span class=\"nowrap\">mcg/mL</span>. (See <a href=\"#H3053721516\" class=\"local\">'Target concentrations'</a> below.)</p><p/><p>There is substantial inter- and intrapatient variability in <a href=\"topic.htm?path=vancomycin-drug-information\" class=\"drug drug_general\">vancomycin</a> pharmacokinetic parameters; therefore, frequent assessment of renal function and individualization of the dosage regimen are needed to optimize efficacy and minimize risk of toxicity.</p><p>In general, for patients with normal renal function, <a href=\"topic.htm?path=vancomycin-drug-information\" class=\"drug drug_general\">vancomycin</a> dosing consists of 15 to 20 <span class=\"nowrap\">mg/kg/dose</span> (based on actual body weight) every 12 hours, not to exceed single doses of 2 g unless measured trough concentrations in serum are below target concentrations.</p><p>In the setting of rapid clearance (such as in burn patients or in younger patients with normal renal function), administration of <a href=\"topic.htm?path=vancomycin-drug-information\" class=\"drug drug_general\">vancomycin</a> every 8 hours may be required to achieve target troughs. In patients with impaired renal function, dose reductions <span class=\"nowrap\">and/or</span> extended dosing intervals are required.</p><p>The optimal method for determining the initial <a href=\"topic.htm?path=vancomycin-drug-information\" class=\"drug drug_general\">vancomycin</a> dose and interval that most reliably achieves target serum trough concentrations is uncertain; protocols vary between institutions [<a href=\"https://www.uptodate.com/contents/vancomycin-parenteral-dosing-monitoring-and-adverse-effects-in-adults/abstract/10\" class=\"abstract_t\">10</a>]. For initial dosing in most hospitalized patients, we use the nomogram outlined in the table (<a href=\"image.htm?imageKey=ID%2F60466\" class=\"graphic graphic_table graphicRef60466 \">table 1</a>), based on actual body weight and creatinine clearance using the Cockcroft-Gault equation (<a href=\"topic.htm?path=calculator-creatinine-clearance-estimate-by-cockcroft-gault-equation-in-adults-and-older-adolescents-age-18-years\" class=\"calc calc_professional\">calculator 1</a>). However, use of the Cockcroft-Gault equation may result in overestimation of vancomycin clearance in older adults and in patients with low muscle mass (eg, amputees, cerebral palsy). In these patients, more conservative (ie, less frequent) dosing <span class=\"nowrap\">and/or</span> use of an alternate method for assessment of renal function is appropriate. Issues related to assessment of renal function are reviewed separately. (See <a href=\"topic.htm?path=assessment-of-kidney-function\" class=\"medical medical_review\">&quot;Assessment of kidney function&quot;</a>.)</p><p>In the setting of stable renal function (and in the absence of significant renal dysfunction), steady-state <a href=\"topic.htm?path=vancomycin-drug-information\" class=\"drug drug_general\">vancomycin</a> serum trough concentrations should be measured prior to the fourth dose following the initial dose or dose adjustment, within 30 minutes prior to infusion [<a href=\"https://www.uptodate.com/contents/vancomycin-parenteral-dosing-monitoring-and-adverse-effects-in-adults/abstract/9\" class=\"abstract_t\">9</a>]. The approach to use of vancomycin serum trough concentrations to guide dose adjustment is discussed below. (See <a href=\"#H1455059606\" class=\"local\">'Dose adjustments'</a> below.)</p><p>In the setting of unstable renal function, the timing of subsequent <a href=\"topic.htm?path=vancomycin-drug-information\" class=\"drug drug_general\">vancomycin</a> dosing following the initial vancomycin dose (15 to 20 <span class=\"nowrap\">mg/kg,</span> not to exceed 2 g) can be determined by timed &quot;spot&quot; (non&ndash;steady-state) serum concentration measurements (a strategy known as &quot;dosing by level&quot;). The timing of the spot concentration should be determined by the direction and rate of change in renal function (as reflected by serum creatinine), generally not exceeding the estimated half-life of the prior dose. The timed spot concentration monitoring is then repeated until renal function is stable and a regular dosing interval can be established.</p><p>Once the target <a href=\"topic.htm?path=vancomycin-drug-information\" class=\"drug drug_general\">vancomycin</a> trough concentration is achieved, vancomycin serum trough concentrations and serum creatinine concentration should be monitored at least weekly for patients in the following circumstances [<a href=\"https://www.uptodate.com/contents/vancomycin-parenteral-dosing-monitoring-and-adverse-effects-in-adults/abstract/11,12\" class=\"abstract_t\">11,12</a>]:</p><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>Patients with invasive infections receiving a prolonged course of <a href=\"topic.htm?path=vancomycin-drug-information\" class=\"drug drug_general\">vancomycin</a> with target trough concentrations 15 to 20 <span class=\"nowrap\">mcg/mL</span></p><p/><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>Patients with fluctuating renal function, fluctuating fluid balance, hemodynamic instability, critical illness, morbid obesity, or receiving dialysis</p><p/><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>Patients at increased risk of nephrotoxicity due to use of concomitant nephrotoxins (such as aminoglycosides)</p><p/><p>For patients with stable renal function who are not in the above categories, repeat <a href=\"topic.htm?path=vancomycin-drug-information\" class=\"drug drug_general\">vancomycin</a> trough concentrations need not be routinely monitored once the target vancomycin trough concentration is achieved. However, routine monitoring of renal function should continue, and development of renal dysfunction should prompt repeat measurement of vancomycin trough concentration followed by dose adjustment as necessary.</p><p>Issues related to <a href=\"topic.htm?path=vancomycin-drug-information\" class=\"drug drug_general\">vancomycin</a> dosing in obese patients are discussed below. (see <a href=\"#H10\" class=\"local\">'Obese patients'</a> below)</p><p class=\"headingAnchor\" id=\"H3269410249\"><span class=\"h2\">General principles</span></p><p class=\"headingAnchor\" id=\"H1922449566\"><span class=\"h3\">Approach to infusion</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span><a href=\"topic.htm?path=vancomycin-drug-information\" class=\"drug drug_general\">Vancomycin</a> dosing consists of intermittent administration; doses are rounded to the nearest 250 mg. In general, the drug should be infused over 0.5 hours for each 500 mg increment (eg, 500 mg over 0.5 hours, 1000 mg over 1 hour). In the setting of red man syndrome, the rate of infusion should be reduced (for example, 500 mg over 1 hour). (See <a href=\"#H902800417\" class=\"local\">'Red man syndrome'</a> below.)</p><p>Thus far, studies of continuous infusion have not demonstrated improvement in patient outcomes compared with intermittent dosing [<a href=\"https://www.uptodate.com/contents/vancomycin-parenteral-dosing-monitoring-and-adverse-effects-in-adults/abstract/2\" class=\"abstract_t\">2</a>]. Use of continuous infusion may be associated with reduction in red man syndrome and nephrotoxicity, although further clinical trials are needed before this method can be employed routinely [<a href=\"https://www.uptodate.com/contents/vancomycin-parenteral-dosing-monitoring-and-adverse-effects-in-adults/abstract/13,14\" class=\"abstract_t\">13,14</a>].</p><p class=\"headingAnchor\" id=\"H3722373455\"><span class=\"h3\">Loading dose</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>Use of a loading <a href=\"topic.htm?path=vancomycin-drug-information\" class=\"drug drug_general\">vancomycin</a> dose (25 to 30 <span class=\"nowrap\">mg/kg,</span> rounded to the nearest 250 mg increment) is appropriate for patients with invasive infection (such as bacteremia, endocarditis, or osteomyelitis) <span class=\"nowrap\">and/or</span> in patients with critical illness [<a href=\"https://www.uptodate.com/contents/vancomycin-parenteral-dosing-monitoring-and-adverse-effects-in-adults/abstract/2,3,15\" class=\"abstract_t\">2,3,15</a>]. (See <a href=\"#H8\" class=\"local\">'Clinical approach'</a> above.)</p><p>Administration of a loading dose may facilitate a more rapid attainment of <a href=\"topic.htm?path=vancomycin-drug-information\" class=\"drug drug_general\">vancomycin</a> serum trough concentrations of 15 to 20 <span class=\"nowrap\">mcg/mL,</span> though administration of a loading dose does not affect the time to steady state [<a href=\"https://www.uptodate.com/contents/vancomycin-parenteral-dosing-monitoring-and-adverse-effects-in-adults/abstract/16\" class=\"abstract_t\">16</a>]. This approach may be particularly useful for patients with critical illness, especially in the setting of higher anticipated volumes of distribution (such as patients with serious burns or fluid overload). Use of a single vancomycin loading dose has not been associated with increased risk of nephrotoxicity [<a href=\"https://www.uptodate.com/contents/vancomycin-parenteral-dosing-monitoring-and-adverse-effects-in-adults/abstract/17,18\" class=\"abstract_t\">17,18</a>].</p><p class=\"headingAnchor\" id=\"H1884293851\"><span class=\"h3\">Serum concentration monitoring</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>Assessment of <a href=\"topic.htm?path=vancomycin-drug-information\" class=\"drug drug_general\">vancomycin</a> serum trough concentrations is especially warranted for individualizing vancomycin therapy in the following circumstances:</p><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>Critical illness</p><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>Severe or invasive infection</p><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>Impaired or fluctuating renal function</p><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>Morbid obesity (body mass index &ge;40 <span class=\"nowrap\">kg/m<sup>2</sup>)</span></p><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>Advanced age</p><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>Lack of adequate clinical response after three to five days of therapy</p><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>Use of concurrent nephrotoxic medications (examples include aminoglycosides, <a href=\"topic.htm?path=piperacillin-and-tazobactam-sodium-drug-information\" class=\"drug drug_general\">piperacillin-tazobactam</a>, amphotericin B, <a href=\"topic.htm?path=cyclosporine-ciclosporin-drug-information\" class=\"drug drug_general\">cyclosporine</a>, loop diuretics, nonsteroidal anti-inflammatory drugs, and radiocontrast)</p><p/><p>Given the variability in pharmacokinetic parameters and the need to optimize target concentrations, performance of routine therapeutic serum concentration should be performed in patients for whom therapy is expected to continue (usually beyond 72 hours). However, such monitoring has not been definitively established to improve clinical outcomes or reduce the occurrence of vancomycin-associated toxicities (see <a href=\"#H536241036\" class=\"local\">'Pharmacokinetics and pharmacodynamics'</a> below).</p><p class=\"headingAnchor\" id=\"H3053721516\"><span class=\"h4\">Target concentrations</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>The target trough serum concentration depends on the nature of infection:</p><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>For patients with deep-seated infection (such as bacteremia, endocarditis, osteomyelitis, prosthetic joint infection, pneumonia warranting hospitalization, or infections involving the central nervous system), a target trough of 15 to 20 <span class=\"nowrap\">mcg/mL</span> is warranted.</p><p/><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>For patients with nonsevere infection (such as soft tissue infection), a target trough of 10 to 15 <span class=\"nowrap\">mcg/mL</span> is warranted. Achieving a <a href=\"topic.htm?path=vancomycin-drug-information\" class=\"drug drug_general\">vancomycin</a> trough concentration of at least 10 <span class=\"nowrap\">mcg/mL</span> may reduce the emergence of isolates with elevated vancomycin minimum inhibitory concentrations (MICs) [<a href=\"https://www.uptodate.com/contents/vancomycin-parenteral-dosing-monitoring-and-adverse-effects-in-adults/abstract/19,20\" class=\"abstract_t\">19,20</a>].</p><p/><p>Traditionally, trough concentrations (while imprecise) have been considered useful as a surrogate measurement for area under the time-concentration curve (AUC) and are regarded as the most practical method to monitor <a href=\"topic.htm?path=vancomycin-drug-information\" class=\"drug drug_general\">vancomycin</a>. Target trough concentrations are used as a surrogate for the drug's AUC and its relationship to the pathogen's MIC. (See <a href=\"#H536241036\" class=\"local\">'Pharmacokinetics and pharmacodynamics'</a> below.)</p><p>For isolates with <a href=\"topic.htm?path=vancomycin-drug-information\" class=\"drug drug_general\">vancomycin</a> MIC &le;1 <span class=\"nowrap\">mg/L,</span> an AUC:MIC of &ge;400 (the drug's pharmacodynamic target) can generally be achieved with vancomycin trough concentrations of 15 to 20 <span class=\"nowrap\">mcg/mL</span> [<a href=\"https://www.uptodate.com/contents/vancomycin-parenteral-dosing-monitoring-and-adverse-effects-in-adults/abstract/21,22\" class=\"abstract_t\">21,22</a>]. For isolates with a vancomycin MIC &ge;2 <span class=\"nowrap\">mg/L,</span> an AUC:MIC of &ge;400 is not reliably achievable with conventional dosing methods in patients with normal renal function; in such situations, use of an alternate therapeutic agent may be warranted [<a href=\"https://www.uptodate.com/contents/vancomycin-parenteral-dosing-monitoring-and-adverse-effects-in-adults/abstract/21\" class=\"abstract_t\">21</a>]. (See <a href=\"topic.htm?path=methicillin-resistant-staphylococcus-aureus-mrsa-in-adults-treatment-of-bacteremia#H2406416818\" class=\"medical medical_review\">&quot;Methicillin-resistant Staphylococcus aureus (MRSA) in adults: Treatment of bacteremia&quot;, section on 'Borderline vancomycin susceptibility'</a>.)</p><p>There is no role for routine monitoring of peak <a href=\"topic.htm?path=vancomycin-drug-information\" class=\"drug drug_general\">vancomycin</a> concentrations, given the lack of data correlating peak concentrations with efficacy or toxicity and concentration-independent pharmacodynamic properties of the drug [<a href=\"https://www.uptodate.com/contents/vancomycin-parenteral-dosing-monitoring-and-adverse-effects-in-adults/abstract/8\" class=\"abstract_t\">8</a>]. Peak concentrations may be useful for situations in which more precise pharmacokinetic parameter calculations are required for individualized dosing, when used in conjunction with additional serum concentration data (such as a mid-interval or &quot;spot&quot; concentration).</p><p class=\"headingAnchor\" id=\"H1455059606\"><span class=\"h4\">Dose adjustments</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span><a href=\"topic.htm?path=vancomycin-drug-information\" class=\"drug drug_general\">Vancomycin</a> trough concentrations should be used to guide dose adjustments.</p><p>Measurement of a trough concentration that is <strong>below</strong> the target range should prompt an increase in the total daily dose. In general, adjustment of the total daily dose (with no adjustment of the dosing interval) will result in proportional change in the trough concentration (for example, a 50 percent increase in the dose will increase the trough concentration by 50 percent). In contrast, adjustment of the dosing interval does not result in proportional change in the trough concentration; the predicted effect of such adjustment requires a calculation usually performed by pharmacists.</p><p>Measurement of a trough concentration that is <strong>above</strong> the target level should prompt adjustment in the dose as follows:</p><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>For trough concentrations more than 5 <span class=\"nowrap\">mcg/mL</span> above target range, subsequent <a href=\"topic.htm?path=vancomycin-drug-information\" class=\"drug drug_general\">vancomycin</a> doses should be held, and daily vancomycin levels should be repeated until the level is within the target range. Thereafter, a new dosing regimen should be established based on the principles outlined above.</p><p/><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>For trough concentrations within 5 <span class=\"nowrap\">mcg/mL</span> of the target range, a new dosing regimen should be implemented at the next scheduled dose based on the principles outlined above.</p><p/><p>Following dose adjustment, repeat <a href=\"topic.htm?path=vancomycin-drug-information\" class=\"drug drug_general\">vancomycin</a> serum trough concentrations should be measured prior to the fourth dose following the adjustment (in the setting of stable renal function).</p><p class=\"headingAnchor\" id=\"H10\"><span class=\"h3\">Obese patients</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>There is no well-validated, universally accepted nomogram to guide the approach to <a href=\"topic.htm?path=vancomycin-drug-information\" class=\"drug drug_general\">vancomycin</a> dosing in obese patients [<a href=\"https://www.uptodate.com/contents/vancomycin-parenteral-dosing-monitoring-and-adverse-effects-in-adults/abstract/10,23-25\" class=\"abstract_t\">10,23-25</a>]. Our approach is as follows:</p><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span><strong>Loading dose</strong> &ndash; The loading dose, if given, is based on actual body weight (up to a single maximum dose of 3 grams) in all patients who are overweight or obese. (See <a href=\"#H3722373455\" class=\"local\">'Loading dose'</a> above.)</p><p/><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span><strong>Initial maintenance dose</strong> &ndash; For patients with body mass index &ge;25 <span class=\"nowrap\">kg/m<sup>2</sup></span> (<a href=\"topic.htm?path=calculator-body-mass-index-bmi-quetelets-index-in-adults\" class=\"calc calc_professional\">calculator 2</a>), we calculate an ideal body weight (<a href=\"topic.htm?path=calculator-ideal-body-weight-method-of-devine-and-dosing-weight-for-adults\" class=\"calc calc_professional\">calculator 3</a>) and, depending on the result, proceed as follows:</p><p/><p class=\"bulletIndent2\"><span class=\"glyph\">&#8226;</span>For patients with actual body weight &le;125 percent of ideal body weight, the initial maintenance dose is based on actual body weight, according to the nomogram (<a href=\"image.htm?imageKey=ID%2F60466\" class=\"graphic graphic_table graphicRef60466 \">table 1</a>).</p><p/><p class=\"bulletIndent2\"><span class=\"glyph\">&#8226;</span>For patients with actual body weight is &gt;125 percent of ideal body weight, our approach to determining the initial maintenance dose depends on whether the patient weighs up to 100 kg or more than 100 kg:</p><p/><p class=\"bulletIndent3\"><span class=\"glyph\">&#45;</span>For patients &le;100 kg, the initial maintenance dose is based on a calculated &quot;dosing weight&quot; according to the nomogram (<a href=\"image.htm?imageKey=ID%2F60466\" class=\"graphic graphic_table graphicRef60466 \">table 1</a>). (Note that the ideal body weight calculator (<a href=\"topic.htm?path=calculator-ideal-body-weight-method-of-devine-and-dosing-weight-for-adults\" class=\"calc calc_professional\">calculator 3</a>) also calculates the &quot;dosing weight&quot;; refer to the right side of the calculator to locate the dosing weight result.)</p><p/><p class=\"bulletIndent3\"><span class=\"glyph\">&#45;</span>For patients &gt;100 kg, we favor use of individualized dosing regimens based on pharmacokinetic calculations performed by clinical pharmacists. If such services are not available, it is reasonable to use an initial maintenance dose of approximately 30 to 45 <span class=\"nowrap\">mg/kg</span> per day, based on actual body weight, in two or three divided doses for normal renal function [<a href=\"https://www.uptodate.com/contents/vancomycin-parenteral-dosing-monitoring-and-adverse-effects-in-adults/abstract/26\" class=\"abstract_t\">26</a>]. The initial single maintenance dose should not exceed 2 g, irrespective of body weight. Further information on <a href=\"topic.htm?path=vancomycin-drug-information\" class=\"drug drug_general\">vancomycin</a> dosing in the setting of obesity and renal impairment is included separately in the vancomycin drug information monograph.</p><p/><p>Subsequent dose adjustments in obese patients are based on clinical response, kidney function, and serum trough concentration assessments as in nonobese patients [<a href=\"https://www.uptodate.com/contents/vancomycin-parenteral-dosing-monitoring-and-adverse-effects-in-adults/abstract/27,28\" class=\"abstract_t\">27,28</a>]. (See <a href=\"#H1455059606\" class=\"local\">'Dose adjustments'</a> above.)</p><p class=\"headingAnchor\" id=\"H3345648004\"><span class=\"h3\">Patients on renal replacement therapy</span></p><p class=\"headingAnchor\" id=\"H21\"><span class=\"h4\">Hemodialysis</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>For patients on hemodialysis (goal <a href=\"topic.htm?path=vancomycin-drug-information\" class=\"drug drug_general\">vancomycin</a> level 15 to 20 <span class=\"nowrap\">mcg/mL),</span> a loading dose of 25 <span class=\"nowrap\">mg/kg</span> (rounded to the nearest 250 mg increment) should be administered (<a href=\"topic.htm?path=calculator-lean-body-weight-adult-male\" class=\"calc calc_professional\">calculator 4</a> and <a href=\"topic.htm?path=calculator-lean-body-weight-adult-female\" class=\"calc calc_professional\">calculator 5</a>) [<a href=\"https://www.uptodate.com/contents/vancomycin-parenteral-dosing-monitoring-and-adverse-effects-in-adults/abstract/29,30\" class=\"abstract_t\">29,30</a>]. Subsequent dosing depends upon the method and frequency of dialysis:</p><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>For patients receiving intermittent hemodialysis via more permeable high-flux membranes, supplemental <a href=\"topic.htm?path=vancomycin-drug-information\" class=\"drug drug_general\">vancomycin</a> dosing is generally required during the final hour of dialysis (to facilitate the completion of the session) or immediately following each dialysis session [<a href=\"https://www.uptodate.com/contents/vancomycin-parenteral-dosing-monitoring-and-adverse-effects-in-adults/abstract/1,31,32\" class=\"abstract_t\">1,31,32</a>]. The optimal approach is uncertain; in general, for patients receiving thrice-weekly dialysis, many favor administration of vancomycin 10 <span class=\"nowrap\">mg/kg</span> in the last one to two hours of each dialysis session. A vancomycin serum concentration should be obtained prior to the third dialysis session following initiation of therapy, and dose adjustments should be made as summarized in the table (<a href=\"image.htm?imageKey=ID%2F97965\" class=\"graphic graphic_table graphicRef97965 \">table 2</a>).</p><p/><p class=\"bulletIndent1\">Following dose adjustment, repeat <a href=\"topic.htm?path=vancomycin-drug-information\" class=\"drug drug_general\">vancomycin</a> serum concentration should be measured prior to the following dialysis session, with subsequent adjustment (if necessary) according to the principles above. Once the predialysis vancomycin concentration is within the target range, it should be checked weekly. If subsequent concentrations are outside the target range, dose adjustments should be made as outlined above.</p><p/><p class=\"bulletIndent1\">Administration of a fixed <a href=\"topic.htm?path=vancomycin-drug-information\" class=\"drug drug_general\">vancomycin</a> dose following dialysis (such as 500 mg) has been associated with unpredictable serum vancomycin levels, so it may be inadequate for patients receiving vancomycin for treatment of deep-seated infection [<a href=\"https://www.uptodate.com/contents/vancomycin-parenteral-dosing-monitoring-and-adverse-effects-in-adults/abstract/33\" class=\"abstract_t\">33</a>].</p><p/><p class=\"bulletIndent1\">Longer intervals between dialysis sessions (eg, 72 hours rather than 48 hours, such as over a weekend) may result in lower predialysis <a href=\"topic.htm?path=vancomycin-drug-information\" class=\"drug drug_general\">vancomycin</a> concentrations at the subsequent session. In such cases, administration of a higher dose (increased by 250 mg) at the last dialysis session prior to the longer interval is warranted [<a href=\"https://www.uptodate.com/contents/vancomycin-parenteral-dosing-monitoring-and-adverse-effects-in-adults/abstract/29,30,34\" class=\"abstract_t\">29,30,34</a>].</p><p/><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>For patients receiving intermittent hemodialysis via older, less permeable low-flux membranes, <a href=\"topic.htm?path=vancomycin-drug-information\" class=\"drug drug_general\">vancomycin</a> clearance is reduced. Therefore, a therapeutic vancomycin concentration may persist for days. A serum vancomycin concentration should be repeated at each dialysis session. Once the concentration has fallen to the target range, a repeat vancomycin dose (15 to 20 <span class=\"nowrap\">mg/kg</span> intravenously) should be administered [<a href=\"https://www.uptodate.com/contents/vancomycin-parenteral-dosing-monitoring-and-adverse-effects-in-adults/abstract/1,31\" class=\"abstract_t\">1,31</a>].</p><p/><p class=\"headingAnchor\" id=\"H419376098\"><span class=\"h4\">Peritoneal dialysis</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>For patients on peritoneal dialysis, an intravenous loading dose of 25 <span class=\"nowrap\">mg/kg</span> (rounded to the nearest 250 mg increment) should be administered. A <a href=\"topic.htm?path=vancomycin-drug-information\" class=\"drug drug_general\">vancomycin</a> serum concentration should be obtained approximately 48 hours after the loading dose, and subsequent doses (15 to 20 <span class=\"nowrap\">mg/kg</span> intravenously) should be administered based on goal serum concentrations.</p><p>Patients with peritonitis may best be treated via intraperitoneal administration of <a href=\"topic.htm?path=vancomycin-drug-information\" class=\"drug drug_general\">vancomycin</a>. This is discussed further separately. (See <a href=\"topic.htm?path=microbiology-and-therapy-of-peritonitis-in-peritoneal-dialysis\" class=\"medical medical_review\">&quot;Microbiology and therapy of peritonitis in peritoneal dialysis&quot;</a>.)</p><p class=\"headingAnchor\" id=\"H1187413911\"><span class=\"h4\">Continuous renal replacement</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>Forms of continuous renal replacement include continuous arteriovenous hemofiltration (CAVH), continuous venovenous hemofiltration (CVVH), continuous arteriovenous hemodialysis (CAVHD), continuous venovenous hemodialysis (CVVHD), and continuous venovenous hemodiafiltration (CVVHDF).</p><p>An intravenous loading dose of 25 <span class=\"nowrap\">mg/kg</span> (rounded to the nearest 250 mg increment) should be administered. A <a href=\"topic.htm?path=vancomycin-drug-information\" class=\"drug drug_general\">vancomycin</a> serum concentration level should obtained approximately 48 hours after the loading dose, and subsequent doses (15 to 20 <span class=\"nowrap\">mg/kg</span> intravenously) should be administered based on goal serum concentrations.</p><p class=\"headingAnchor\" id=\"H1269346913\"><span class=\"h1\">ADVERSE EFFECTS</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>Adverse effects of parenteral <a href=\"topic.htm?path=vancomycin-drug-information\" class=\"drug drug_general\">vancomycin</a> include rash (due to red man syndrome or true vancomycin sensitivity), infusion-related reactions, nephrotoxicity, and ototoxicity. (See <a href=\"topic.htm?path=vancomycin-hypersensitivity\" class=\"medical medical_review\">&quot;Vancomycin hypersensitivity&quot;</a>.)</p><p>While absorption of oral <a href=\"topic.htm?path=vancomycin-drug-information\" class=\"drug drug_general\">vancomycin</a> is generally limited, its bioavailability may be increased in the setting of colonic inflammation. Adverse effects similar to those observed in the setting of parenteral administration may be observed among patients on oral vancomycin with colonic inflammation associated with <em>Clostridium difficile</em> infection [<a href=\"https://www.uptodate.com/contents/vancomycin-parenteral-dosing-monitoring-and-adverse-effects-in-adults/abstract/35\" class=\"abstract_t\">35</a>].</p><p class=\"headingAnchor\" id=\"H902800417\"><span class=\"h2\">Red man syndrome</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>Red man syndrome is a histamine-mediated flushing during or immediately following infusion of <a href=\"topic.htm?path=vancomycin-drug-information\" class=\"drug drug_general\">vancomycin</a>. Flushing usually involves the face and neck but can involve the entire body. It may be reduced or eliminated by avoiding excessive doses and prolonging the infusion time (eg, administering the drug at a rate of no more than 500 <span class=\"nowrap\">mg/hour;</span> occasionally some patients require an even slower infusion rate) [<a href=\"https://www.uptodate.com/contents/vancomycin-parenteral-dosing-monitoring-and-adverse-effects-in-adults/abstract/36\" class=\"abstract_t\">36</a>]. (See <a href=\"#H1922449566\" class=\"local\">'Approach to infusion'</a> above.)</p><p>Red man syndrome and <a href=\"topic.htm?path=vancomycin-drug-information\" class=\"drug drug_general\">vancomycin</a> hypersensitivity reactions are discussed further separately. (See <a href=\"topic.htm?path=vancomycin-hypersensitivity#H2\" class=\"medical medical_review\">&quot;Vancomycin hypersensitivity&quot;, section on 'Red man syndrome'</a>.)</p><p class=\"headingAnchor\" id=\"H3209587989\"><span class=\"h2\">Nephrotoxicity</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>Acute renal failure attributable to <a href=\"topic.htm?path=vancomycin-drug-information\" class=\"drug drug_general\">vancomycin</a> should prompt discontinuation of the drug. While vancomycin-induced nephrotoxicity is usually reversible, it can be difficult to distinguish between drug-induced nephrotoxicity and acute interstitial nephritis; in addition, worsening renal function can be a marker of uncontrolled infection.</p><p>The nephrotoxic potential of <a href=\"topic.htm?path=vancomycin-drug-information\" class=\"drug drug_general\">vancomycin</a> is not fully understood. Some studies of contemporary vancomycin formulations have observed acute decline in renal function associated with vancomycin monotherapy in 5 to 15 percent of patients [<a href=\"https://www.uptodate.com/contents/vancomycin-parenteral-dosing-monitoring-and-adverse-effects-in-adults/abstract/37-40\" class=\"abstract_t\">37-40</a>]. Nephrotoxicity has been associated with steady-state vancomycin trough concentrations exceeding 15 <span class=\"nowrap\">mcg/mL</span> [<a href=\"https://www.uptodate.com/contents/vancomycin-parenteral-dosing-monitoring-and-adverse-effects-in-adults/abstract/41-44\" class=\"abstract_t\">41-44</a>].</p><p>Total daily <a href=\"topic.htm?path=vancomycin-drug-information\" class=\"drug drug_general\">vancomycin</a> dose &gt;4 g has been shown to be a risk factor for nephrotoxicity [<a href=\"https://www.uptodate.com/contents/vancomycin-parenteral-dosing-monitoring-and-adverse-effects-in-adults/abstract/43\" class=\"abstract_t\">43</a>]. It is unclear whether this observation reflects difficulties in estimating renal function in obese patients or an increased risk in obese patients (as a consequence of weight-based dosing). Additional risk factors for nephrotoxicity associated with vancomycin include duration of therapy, concurrent use of other nephrotoxic agents, presence of underlying renal dysfunction, and critical illness [<a href=\"https://www.uptodate.com/contents/vancomycin-parenteral-dosing-monitoring-and-adverse-effects-in-adults/abstract/45\" class=\"abstract_t\">45</a>].</p><p>Nephrotoxicity associated with coadministration of <a href=\"topic.htm?path=vancomycin-drug-information\" class=\"drug drug_general\">vancomycin</a> and an aminoglycoside is well established. The incidence of acute renal failure in this setting may be as high as 20 to 30 percent [<a href=\"https://www.uptodate.com/contents/vancomycin-parenteral-dosing-monitoring-and-adverse-effects-in-adults/abstract/37,40,46\" class=\"abstract_t\">37,40,46</a>].</p><p>Nephrotoxicity associated with coadministration of <a href=\"topic.htm?path=vancomycin-drug-information\" class=\"drug drug_general\">vancomycin</a> and <a href=\"topic.htm?path=piperacillin-and-tazobactam-sodium-drug-information\" class=\"drug drug_general\">piperacillin-tazobactam</a> has been described; the odds ratio of acute kidney injury (AKI) associated with coadministration of these drugs is approximately 3.5 (relative to vancomycin monotherapy and coadministration with other beta-lactams, notably <a href=\"topic.htm?path=cefepime-drug-information\" class=\"drug drug_general\">cefepime</a>) [<a href=\"https://www.uptodate.com/contents/vancomycin-parenteral-dosing-monitoring-and-adverse-effects-in-adults/abstract/47-57\" class=\"abstract_t\">47-57</a>]. Use of prolonged infusions of piperacillin-tazobactam does not appear to affect the rate of AKI when coadministered with vancomycin [<a href=\"https://www.uptodate.com/contents/vancomycin-parenteral-dosing-monitoring-and-adverse-effects-in-adults/abstract/58\" class=\"abstract_t\">58</a>]. Therefore, in patients receiving vancomycin who also require antimicrobial therapy against gram-negative pathogens, use of a cephalosporin (rather than piperacillin-tazobactam) may avoid the increased risk of nephrotoxicity; if anaerobic coverage is needed, <a href=\"topic.htm?path=metronidazole-drug-information\" class=\"drug drug_general\">metronidazole</a> can be added to this alternative regimen. This alternative regimen would lack activity against some enterococci (notably <em>E. faecalis</em>) and reduce activity against methicillin-susceptible <em>S. aureus</em> (if second- or third-generation cephalosporins such as <a href=\"topic.htm?path=ceftazidime-drug-information\" class=\"drug drug_general\">ceftazidime</a> or cefepime are used).</p><p class=\"headingAnchor\" id=\"H2072386946\"><span class=\"h2\">Ototoxicity</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>Ototoxicity has been observed in association with <a href=\"topic.htm?path=vancomycin-drug-information\" class=\"drug drug_general\">vancomycin</a> administration; ototoxicity attributable to vancomycin should prompt discontinuation of the drug [<a href=\"https://www.uptodate.com/contents/vancomycin-parenteral-dosing-monitoring-and-adverse-effects-in-adults/abstract/59,60\" class=\"abstract_t\">59,60</a>]. Potential risk factors for vancomycin-induced ototoxicity include preexisting hearing abnormalities and underlying renal dysfunction [<a href=\"https://www.uptodate.com/contents/vancomycin-parenteral-dosing-monitoring-and-adverse-effects-in-adults/abstract/46,61,62\" class=\"abstract_t\">46,61,62</a>].</p><p>Ototoxicity associated with <a href=\"topic.htm?path=vancomycin-drug-information\" class=\"drug drug_general\">vancomycin</a> is more common in older patients. In one report including 89 patients who underwent audiograms after an average of 27 days of vancomycin administration, high-frequency hearing loss was observed among patients &gt;53 years of age in 19 percent of cases; no hearing loss was observed among patients &lt;53 years of age [<a href=\"https://www.uptodate.com/contents/vancomycin-parenteral-dosing-monitoring-and-adverse-effects-in-adults/abstract/60\" class=\"abstract_t\">60</a>]. Another study including 130 newborns who received vancomycin and followed with audiology screening demonstrated no association between vancomycin and ototoxicity [<a href=\"https://www.uptodate.com/contents/vancomycin-parenteral-dosing-monitoring-and-adverse-effects-in-adults/abstract/63\" class=\"abstract_t\">63</a>].</p><p>In the absence of tinnitus or ataxia, clinical detection of <a href=\"topic.htm?path=vancomycin-drug-information\" class=\"drug drug_general\">vancomycin</a> ototoxicity is challenging; in the absence of audiometric testing, high-frequency hearing loss may not be detected. In addition, older adults at greatest risk often suffer high-frequency hearing loss in the absence of vancomycin therapy.</p><p class=\"headingAnchor\" id=\"H536241036\"><span class=\"h1\">PHARMACOKINETICS AND PHARMACODYNAMICS</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span><a href=\"topic.htm?path=vancomycin-drug-information\" class=\"drug drug_general\">Vancomycin</a> is distributed widely to various tissues and body fluids, with a volume of distribution ranging from 0.4 to 1 <span class=\"nowrap\">L/kg</span> [<a href=\"https://www.uptodate.com/contents/vancomycin-parenteral-dosing-monitoring-and-adverse-effects-in-adults/abstract/64\" class=\"abstract_t\">64</a>]. There is substantial inter-patient variability in vancomycin pharmacokinetic parameters.</p><p>Penetration of <a href=\"topic.htm?path=vancomycin-drug-information\" class=\"drug drug_general\">vancomycin</a> varies by site and concomitant disease states. For example, limited cerebrospinal fluid penetration may be enhanced by the presence of inflamed meninges. Penetration of vancomycin into soft tissue may be significantly impaired in patients with diabetes [<a href=\"https://www.uptodate.com/contents/vancomycin-parenteral-dosing-monitoring-and-adverse-effects-in-adults/abstract/65\" class=\"abstract_t\">65</a>]. Vancomycin penetration into lung tissue is limited relative to that of simultaneous serum concentration (the ratio of lung tissue to serum concentration is about 0.25) [<a href=\"https://www.uptodate.com/contents/vancomycin-parenteral-dosing-monitoring-and-adverse-effects-in-adults/abstract/66\" class=\"abstract_t\">66</a>].</p><p>The primary route of <a href=\"topic.htm?path=vancomycin-drug-information\" class=\"drug drug_general\">vancomycin</a> elimination is via renal excretion of unchanged drug, and the rate of elimination is directly related to creatinine clearance [<a href=\"https://www.uptodate.com/contents/vancomycin-parenteral-dosing-monitoring-and-adverse-effects-in-adults/abstract/3\" class=\"abstract_t\">3</a>]. Patients with altered vancomycin clearance include patients with critical illness, patients with burns, patients on dialysis, and older adults [<a href=\"https://www.uptodate.com/contents/vancomycin-parenteral-dosing-monitoring-and-adverse-effects-in-adults/abstract/67\" class=\"abstract_t\">67</a>].</p><p>Clinical and microbiologic efficacy are best predicted by the ratio of area under the time-concentration curve (AUC) to minimum inhibitory concentration (MIC; AUC:MIC) [<a href=\"https://www.uptodate.com/contents/vancomycin-parenteral-dosing-monitoring-and-adverse-effects-in-adults/abstract/22,68-70\" class=\"abstract_t\">22,68-70</a>]. In general, the rate of bacterial killing depends primarily on time of concentration exceeding the organism's MIC [<a href=\"https://www.uptodate.com/contents/vancomycin-parenteral-dosing-monitoring-and-adverse-effects-in-adults/abstract/2,71\" class=\"abstract_t\">2,71</a>]. Dosing based on AUC:MIC in routine clinical practice is problematic, since multiple serum concentrations are required for accurate determination of <a href=\"topic.htm?path=vancomycin-drug-information\" class=\"drug drug_general\">vancomycin</a> AUC, and MIC data are not available for patients receiving empiric therapy. Therefore, trough concentrations are used as a surrogate measurement for AUC. (See <a href=\"#H3053721516\" class=\"local\">'Target concentrations'</a> above.)</p><p>The goal AUC:MIC ratio is affected by the method used to determine the AUC and MIC; broth microdilution is a common technique [<a href=\"https://www.uptodate.com/contents/vancomycin-parenteral-dosing-monitoring-and-adverse-effects-in-adults/abstract/72\" class=\"abstract_t\">72</a>]. Some studies suggest that a ratio of AUC to MIC of &ge;400 may be desirable [<a href=\"https://www.uptodate.com/contents/vancomycin-parenteral-dosing-monitoring-and-adverse-effects-in-adults/abstract/68,70,73\" class=\"abstract_t\">68,70,73</a>]. Higher ratios (&gt;600) may be required in patients with endocarditis due to methicillin-resistant <em>S. aureus </em>(MRSA) [<a href=\"https://www.uptodate.com/contents/vancomycin-parenteral-dosing-monitoring-and-adverse-effects-in-adults/abstract/69\" class=\"abstract_t\">69</a>]; however, such targets are controversial because their attainment is not always associated with successful clinical outcome and is associated with increased risk of nephrotoxicity, particularly when the <a href=\"topic.htm?path=vancomycin-drug-information\" class=\"drug drug_general\">vancomycin</a> MIC is &gt;1 <span class=\"nowrap\">mcg/mL</span> [<a href=\"https://www.uptodate.com/contents/vancomycin-parenteral-dosing-monitoring-and-adverse-effects-in-adults/abstract/74\" class=\"abstract_t\">74</a>].</p><p>Estimation of AUC has been described using a formula that utilizes a creatinine clearance estimate and <a href=\"topic.htm?path=vancomycin-drug-information\" class=\"drug drug_general\">vancomycin</a> dose [<a href=\"https://www.uptodate.com/contents/vancomycin-parenteral-dosing-monitoring-and-adverse-effects-in-adults/abstract/22,68\" class=\"abstract_t\">22,68</a>]. In addition, the use of computer software has been described employing Bayesian pharmacokinetics and population modeling requiring one or two timed concentrations obtained at steady state [<a href=\"https://www.uptodate.com/contents/vancomycin-parenteral-dosing-monitoring-and-adverse-effects-in-adults/abstract/75\" class=\"abstract_t\">75</a>].</p><p>Lack of correlation between trough concentrations and AUC has been observed in some studies [<a href=\"https://www.uptodate.com/contents/vancomycin-parenteral-dosing-monitoring-and-adverse-effects-in-adults/abstract/75-79\" class=\"abstract_t\">75-79</a>]. In one systematic review including 2003 patients with invasive MRSA infection, no difference in all-cause mortality was observed between patients with low and high <a href=\"topic.htm?path=vancomycin-drug-information\" class=\"drug drug_general\">vancomycin</a> trough concentrations (&lt;15 <span class=\"nowrap\">mcg/mL</span> versus &ge;15 <span class=\"nowrap\">mcg/mL)</span> [<a href=\"https://www.uptodate.com/contents/vancomycin-parenteral-dosing-monitoring-and-adverse-effects-in-adults/abstract/76\" class=\"abstract_t\">76</a>]. Similarly, another meta-analysis including 1677 patients with <em>S. aureus</em> bacteremia noted no correlation among high vancomycin trough concentrations (&gt;15 <span class=\"nowrap\">mcg/mL)</span> and rates of treatment failure, persistent bacteremia, or mortality [<a href=\"https://www.uptodate.com/contents/vancomycin-parenteral-dosing-monitoring-and-adverse-effects-in-adults/abstract/77\" class=\"abstract_t\">77</a>].</p><p>Clinical failure of <a href=\"topic.htm?path=vancomycin-drug-information\" class=\"drug drug_general\">vancomycin</a> has been observed in patients with infection due to <em>S. aureus</em> isolates with MIC &ge;2 <span class=\"nowrap\">mcg/mL</span> [<a href=\"https://www.uptodate.com/contents/vancomycin-parenteral-dosing-monitoring-and-adverse-effects-in-adults/abstract/41,80-82\" class=\"abstract_t\">41,80-82</a>]. In addition, suboptimal exposure of <em>S. aureus</em> to vancomycin may facilitate the emergence of isolates expressing intermediate or heteroresistance to glycopeptides [<a href=\"https://www.uptodate.com/contents/vancomycin-parenteral-dosing-monitoring-and-adverse-effects-in-adults/abstract/11,83\" class=\"abstract_t\">11,83</a>]. (See <a href=\"topic.htm?path=overview-of-antibacterial-susceptibility-testing#H1897544320\" class=\"medical medical_review\">&quot;Overview of antibacterial susceptibility testing&quot;, section on 'Heteroresistance'</a>.)</p><p class=\"headingAnchor\" id=\"H22\"><span class=\"h1\">SUMMARY</span></p><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>The clinical approach to <a href=\"topic.htm?path=vancomycin-drug-information\" class=\"drug drug_general\">vancomycin</a> dosing is based on the type and severity of infection, patient weight, and renal function. (See <a href=\"#H8\" class=\"local\">'Clinical approach'</a> above and <a href=\"#H3053721516\" class=\"local\">'Target concentrations'</a> above.)</p><p/><p class=\"bulletIndent2\"><span class=\"glyph\">&#8226;</span>For patients with deep-seated infection (including bacteremia, endocarditis, osteomyelitis, prosthetic joint infection, pneumonia warranting hospitalization, infection involving the central nervous system, <span class=\"nowrap\">and/or</span> critical illness), an initial <a href=\"topic.htm?path=vancomycin-drug-information\" class=\"drug drug_general\">vancomycin</a> loading dose (25 to 30 <span class=\"nowrap\">mg/kg,</span> rounded to the nearest 250 mg increment) may be administered. Thereafter, intermittent maintenance dosing should be administered to achieve a target serum trough concentration of 15 to 20 <span class=\"nowrap\">mcg/mL</span>.</p><p/><p class=\"bulletIndent2\"><span class=\"glyph\">&#8226;</span>For patients with nonsevere infection (such as soft tissue infection), a loading <a href=\"topic.htm?path=vancomycin-drug-information\" class=\"drug drug_general\">vancomycin</a> dose is not necessary. Vancomycin should be administered intermittently to achieve a serum target trough concentration of 10 to 15 <span class=\"nowrap\">mcg/mL</span>.</p><p/><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>The <a href=\"topic.htm?path=vancomycin-drug-information\" class=\"drug drug_general\">vancomycin</a> dose and interval are determined by the patient&rsquo;s glomerular filtration rate (<a href=\"topic.htm?path=calculator-creatinine-clearance-estimate-by-cockcroft-gault-equation-in-adults-and-older-adolescents-age-18-years\" class=\"calc calc_professional\">calculator 1</a>) and actual body weight, according to the nomogram outlined in the table (<a href=\"image.htm?imageKey=ID%2F60466\" class=\"graphic graphic_table graphicRef60466 \">table 1</a>). In general, vancomycin dosing consists of 15 to 20 <span class=\"nowrap\">mg/kg/dose</span> every 8 to 12 hours, not to exceed single doses of 2 g unless measured trough concentrations in serum are below target concentrations. (See <a href=\"#H8\" class=\"local\">'Clinical approach'</a> above.)</p><p/><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>In the setting of stable renal function, <a href=\"topic.htm?path=vancomycin-drug-information\" class=\"drug drug_general\">vancomycin</a> serum trough concentrations should be measured prior to the fourth dose following the initial dose or dose adjustment, within 30 minutes prior to infusion. In the setting of unstable renal function, the timing of subsequent vancomycin dosing following the initial vancomycin dose can be determined by timed &quot;spot&quot; (non&ndash;steady-state) serum concentration measurements. (See <a href=\"#H8\" class=\"local\">'Clinical approach'</a> above.)</p><p/><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>Use of a loading <a href=\"topic.htm?path=vancomycin-drug-information\" class=\"drug drug_general\">vancomycin</a> dose (25 to 30 <span class=\"nowrap\">mg/kg,</span> rounded to the nearest 250 mg increment) is appropriate for patients with deep-seated infection (such as bacteremia, endocarditis, or osteomyelitis) <span class=\"nowrap\">and/or</span> critical illness. Administration of a loading dose may facilitate a more rapid attainment of vancomycin serum trough concentrations of 15 to 20 <span class=\"nowrap\">mcg/mL,</span> though administration of a loading dose does not affect the time to steady state (See <a href=\"#H3722373455\" class=\"local\">'Loading dose'</a> above.)</p><p/><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>Measurement of a trough concentration outside the target range should prompt adjustment in the total daily dose. In general, adjustment of the total daily dose (with no adjustment of the dosing interval) will result in proportional change in the trough concentration (for example, a 50 percent increase in the dose will increase the trough concentration by 50 percent). (See <a href=\"#H1455059606\" class=\"local\">'Dose adjustments'</a> above.)</p><p/><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>Issues related to <a href=\"topic.htm?path=vancomycin-drug-information\" class=\"drug drug_general\">vancomycin</a> dosing in obese patients and patients on renal replacement therapy are discussed above. (See <a href=\"#H10\" class=\"local\">'Obese patients'</a> above and <a href=\"#H3345648004\" class=\"local\">'Patients on renal replacement therapy'</a> above.)</p><p/><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>Once the target <a href=\"topic.htm?path=vancomycin-drug-information\" class=\"drug drug_general\">vancomycin</a> trough concentration is achieved, vancomycin serum trough concentrations and serum creatinine concentration should be monitored at least weekly for patients with invasive infection, clinical instability, renal dysfunction, or morbid obesity as well as for patients on concomitant nephrotoxins. (See <a href=\"#H8\" class=\"local\">'Clinical approach'</a> above.)</p><p/><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>Adverse effects of parenteral <a href=\"topic.htm?path=vancomycin-drug-information\" class=\"drug drug_general\">vancomycin</a> include rash (due to red man syndrome or true vancomycin sensitivity), infusion-related reactions, nephrotoxicity, and ototoxicity. (See <a href=\"#H1269346913\" class=\"local\">'Adverse effects'</a> above.)</p><p/></div><div id=\"topicAgreement\">Use of UpToDate is subject to the <a href=\"https://www.uptodate.com/legal/license\" class=\"licenseLink\" id=\"sla_in_page\">Subscription and License Agreement</a>.</div><div id=\"references\" class=\"headingAnchor\"><h1>REFERENCES</h1><ol id=\"reference\"><li><a href=\"https://www.uptodate.com/contents/vancomycin-parenteral-dosing-monitoring-and-adverse-effects-in-adults/abstract/1\" class=\"nounderline abstract_t\">Barth RH, DeVincenzo N. Use of vancomycin in high-flux hemodialysis: experience with 130 courses of therapy. Kidney Int 1996; 50:929.</a></li><li><a href=\"https://www.uptodate.com/contents/vancomycin-parenteral-dosing-monitoring-and-adverse-effects-in-adults/abstract/2\" class=\"nounderline abstract_t\">Rybak MJ, Lomaestro BM, Rotschafer JC, et al. Therapeutic monitoring of vancomycin in adults summary of consensus recommendations from the American Society of Health-System Pharmacists, the Infectious Diseases Society of America, and the Society of Infectious Diseases Pharmacists. Pharmacotherapy 2009; 29:1275.</a></li><li><a href=\"https://www.uptodate.com/contents/vancomycin-parenteral-dosing-monitoring-and-adverse-effects-in-adults/abstract/3\" class=\"nounderline abstract_t\">Matzke GR, McGory RW, Halstenson CE, Keane WF. Pharmacokinetics of vancomycin in patients with various degrees of renal function. Antimicrob Agents Chemother 1984; 25:433.</a></li><li><a href=\"https://www.uptodate.com/contents/vancomycin-parenteral-dosing-monitoring-and-adverse-effects-in-adults/abstract/4\" class=\"nounderline abstract_t\">Moellering RC Jr, Krogstad DJ, Greenblatt DJ. Vancomycin therapy in patients with impaired renal function: a nomogram for dosage. Ann Intern Med 1981; 94:343.</a></li><li><a href=\"https://www.uptodate.com/contents/vancomycin-parenteral-dosing-monitoring-and-adverse-effects-in-adults/abstract/5\" class=\"nounderline abstract_t\">Lake KD, Peterson CD. A simplified dosing method for initiating vancomycin therapy. Pharmacotherapy 1985; 5:340.</a></li><li><a href=\"https://www.uptodate.com/contents/vancomycin-parenteral-dosing-monitoring-and-adverse-effects-in-adults/abstract/6\" class=\"nounderline abstract_t\">Pryka RD, Rodvold KA, Erdman SM. An updated comparison of drug dosing methods. Part IV: Vancomycin. Clin Pharmacokinet 1991; 20:463.</a></li><li><a href=\"https://www.uptodate.com/contents/vancomycin-parenteral-dosing-monitoring-and-adverse-effects-in-adults/abstract/7\" class=\"nounderline abstract_t\">Glatard A, Bourguignon L, Jelliffe RW, et al. Influence of renal function estimation on pharmacokinetic modeling of vancomycin in elderly patients. Antimicrob Agents Chemother 2015; 59:2986.</a></li><li><a href=\"https://www.uptodate.com/contents/vancomycin-parenteral-dosing-monitoring-and-adverse-effects-in-adults/abstract/8\" class=\"nounderline abstract_t\">Rybak M, Lomaestro B, Rotschafer JC, et al. Therapeutic monitoring of vancomycin in adult patients: a consensus review of the American Society of Health-System Pharmacists, the Infectious Diseases Society of America, and the Society of Infectious Diseases Pharmacists. Am J Health Syst Pharm 2009; 66:82.</a></li><li><a href=\"https://www.uptodate.com/contents/vancomycin-parenteral-dosing-monitoring-and-adverse-effects-in-adults/abstract/9\" class=\"nounderline abstract_t\">Liu C, Bayer A, Cosgrove SE, et al. Clinical practice guidelines by the infectious diseases society of america for the treatment of methicillin-resistant Staphylococcus aureus infections in adults and children. Clin Infect Dis 2011; 52:e18.</a></li><li><a href=\"https://www.uptodate.com/contents/vancomycin-parenteral-dosing-monitoring-and-adverse-effects-in-adults/abstract/10\" class=\"nounderline abstract_t\">Elyasi S, Khalili H. Vancomycin dosing nomograms targeting high serum trough levels in different populations: pros and cons. Eur J Clin Pharmacol 2016; 72:777.</a></li><li><a href=\"https://www.uptodate.com/contents/vancomycin-parenteral-dosing-monitoring-and-adverse-effects-in-adults/abstract/11\" class=\"nounderline abstract_t\">Howden BP, Ward PB, Charles PG, et al. Treatment outcomes for serious infections caused by methicillin-resistant Staphylococcus aureus with reduced vancomycin susceptibility. Clin Infect Dis 2004; 38:521.</a></li><li><a href=\"https://www.uptodate.com/contents/vancomycin-parenteral-dosing-monitoring-and-adverse-effects-in-adults/abstract/12\" class=\"nounderline abstract_t\">Moellering RC Jr. Monitoring serum vancomycin levels: climbing the mountain because it is there? Clin Infect Dis 1994; 18:544.</a></li><li><a href=\"https://www.uptodate.com/contents/vancomycin-parenteral-dosing-monitoring-and-adverse-effects-in-adults/abstract/13\" class=\"nounderline abstract_t\">Cataldo MA, Tacconelli E, Grilli E, et al. Continuous versus intermittent infusion of vancomycin for the treatment of Gram-positive infections: systematic review and meta-analysis. J Antimicrob Chemother 2012; 67:17.</a></li><li><a href=\"https://www.uptodate.com/contents/vancomycin-parenteral-dosing-monitoring-and-adverse-effects-in-adults/abstract/14\" class=\"nounderline abstract_t\">Hao JJ, Chen H, Zhou JX. Continuous versus intermittent infusion of vancomycin in adult patients: A systematic review and meta-analysis. Int J Antimicrob Agents 2016; 47:28.</a></li><li><a href=\"https://www.uptodate.com/contents/vancomycin-parenteral-dosing-monitoring-and-adverse-effects-in-adults/abstract/15\" class=\"nounderline abstract_t\">Pea F, Viale P. The antimicrobial therapy puzzle: could pharmacokinetic-pharmacodynamic relationships be helpful in addressing the issue of appropriate pneumonia treatment in critically ill patients? Clin Infect Dis 2006; 42:1764.</a></li><li><a href=\"https://www.uptodate.com/contents/vancomycin-parenteral-dosing-monitoring-and-adverse-effects-in-adults/abstract/16\" class=\"nounderline abstract_t\">Reardon J, Lau TT, Ensom MH. Vancomycin loading doses: a systematic review. Ann Pharmacother 2015; 49:557.</a></li><li><a href=\"https://www.uptodate.com/contents/vancomycin-parenteral-dosing-monitoring-and-adverse-effects-in-adults/abstract/17\" class=\"nounderline abstract_t\">Rosini JM, Davis JJ, Muenzer J, et al. High Single-dose Vancomycin Loading Is Not Associated With Increased Nephrotoxicity in Emergency Department Sepsis Patients. Acad Emerg Med 2016; 23:744.</a></li><li><a href=\"https://www.uptodate.com/contents/vancomycin-parenteral-dosing-monitoring-and-adverse-effects-in-adults/abstract/18\" class=\"nounderline abstract_t\">Rosini JM, Laughner J, Levine BJ, et al. A randomized trial of loading vancomycin in the emergency department. Ann Pharmacother 2015; 49:6.</a></li><li><a href=\"https://www.uptodate.com/contents/vancomycin-parenteral-dosing-monitoring-and-adverse-effects-in-adults/abstract/19\" class=\"nounderline abstract_t\">Tsuji BT, Rybak MJ, Lau KL, Sakoulas G. Evaluation of accessory gene regulator (agr) group and function in the proclivity towards vancomycin intermediate resistance in Staphylococcus aureus. Antimicrob Agents Chemother 2007; 51:1089.</a></li><li><a href=\"https://www.uptodate.com/contents/vancomycin-parenteral-dosing-monitoring-and-adverse-effects-in-adults/abstract/20\" class=\"nounderline abstract_t\">Sakoulas G, Eliopoulos GM, Moellering RC Jr, et al. Staphylococcus aureus accessory gene regulator (agr) group II: is there a relationship to the development of intermediate-level glycopeptide resistance? J Infect Dis 2003; 187:929.</a></li><li><a href=\"https://www.uptodate.com/contents/vancomycin-parenteral-dosing-monitoring-and-adverse-effects-in-adults/abstract/21\" class=\"nounderline abstract_t\">Mohr JF, Murray BE. Point: Vancomycin is not obsolete for the treatment of infection caused by methicillin-resistant Staphylococcus aureus. Clin Infect Dis 2007; 44:1536.</a></li><li><a href=\"https://www.uptodate.com/contents/vancomycin-parenteral-dosing-monitoring-and-adverse-effects-in-adults/abstract/22\" class=\"nounderline abstract_t\">Holmes NE, Turnidge JD, Munckhof WJ, et al. Vancomycin AUC/MIC ratio and 30-day mortality in patients with Staphylococcus aureus bacteremia. Antimicrob Agents Chemother 2013; 57:1654.</a></li><li><a href=\"https://www.uptodate.com/contents/vancomycin-parenteral-dosing-monitoring-and-adverse-effects-in-adults/abstract/23\" class=\"nounderline abstract_t\">Morrill HJ, Caffrey AR, Noh E, LaPlante KL. Vancomycin Dosing Considerations in a Real-World Cohort of Obese and Extremely Obese Patients. Pharmacotherapy 2015; 35:869.</a></li><li><a href=\"https://www.uptodate.com/contents/vancomycin-parenteral-dosing-monitoring-and-adverse-effects-in-adults/abstract/24\" class=\"nounderline abstract_t\">Adane ED, Herald M, Koura F. Pharmacokinetics of vancomycin in extremely obese patients with suspected or confirmed Staphylococcus aureus infections. Pharmacotherapy 2015; 35:127.</a></li><li><a href=\"https://www.uptodate.com/contents/vancomycin-parenteral-dosing-monitoring-and-adverse-effects-in-adults/abstract/25\" class=\"nounderline abstract_t\">Hong J, Krop LC, Johns T, Pai MP. Individualized vancomycin dosing in obese patients: a two-sample measurement approach improves target attainment. Pharmacotherapy 2015; 35:455.</a></li><li><a href=\"https://www.uptodate.com/contents/vancomycin-parenteral-dosing-monitoring-and-adverse-effects-in-adults/abstract/26\" class=\"nounderline abstract_t\">Rybak MJ, Lomaestro BM, Rotschafer JC, et al. Vancomycin therapeutic guidelines: a summary of consensus recommendations from the infectious diseases Society of America, the American Society of Health-System Pharmacists, and the Society of Infectious Diseases Pharmacists. Clin Infect Dis 2009; 49:325.</a></li><li><a href=\"https://www.uptodate.com/contents/vancomycin-parenteral-dosing-monitoring-and-adverse-effects-in-adults/abstract/27\" class=\"nounderline abstract_t\">Hall RG 2nd, Payne KD, Bain AM, et al. Multicenter evaluation of vancomycin dosing: emphasis on obesity. Am J Med 2008; 121:515.</a></li><li><a href=\"https://www.uptodate.com/contents/vancomycin-parenteral-dosing-monitoring-and-adverse-effects-in-adults/abstract/28\" class=\"nounderline abstract_t\">Blouin RA, Bauer LA, Miller DD, et al. Vancomycin pharmacokinetics in normal and morbidly obese subjects. Antimicrob Agents Chemother 1982; 21:575.</a></li><li><a href=\"https://www.uptodate.com/contents/vancomycin-parenteral-dosing-monitoring-and-adverse-effects-in-adults/abstract/29\" class=\"nounderline abstract_t\">Vandecasteele SJ, De Bacquer D, De Vriese AS. Implementation of a dose calculator for vancomycin to achieve target trough levels of 15-20 microg/mL in persons undergoing hemodialysis. Clin Infect Dis 2011; 53:124.</a></li><li><a href=\"https://www.uptodate.com/contents/vancomycin-parenteral-dosing-monitoring-and-adverse-effects-in-adults/abstract/30\" class=\"nounderline abstract_t\">Brown M, Polisetty R, Gracely EJ, et al. Weight-based loading of vancomycin in patients on hemodialysis. Clin Infect Dis 2011; 53:164.</a></li><li><a href=\"https://www.uptodate.com/contents/vancomycin-parenteral-dosing-monitoring-and-adverse-effects-in-adults/abstract/31\" class=\"nounderline abstract_t\">Quale JM, O'Halloran JJ, DeVincenzo N, Barth RH. Removal of vancomycin by high-flux hemodialysis membranes. Antimicrob Agents Chemother 1992; 36:1424.</a></li><li><a href=\"https://www.uptodate.com/contents/vancomycin-parenteral-dosing-monitoring-and-adverse-effects-in-adults/abstract/32\" class=\"nounderline abstract_t\">Zelenitsky SA, Ariano RE, McCrae ML, Vercaigne LM. Initial vancomycin dosing protocol to achieve therapeutic serum concentrations in patients undergoing hemodialysis. Clin Infect Dis 2012; 55:527.</a></li><li><a href=\"https://www.uptodate.com/contents/vancomycin-parenteral-dosing-monitoring-and-adverse-effects-in-adults/abstract/33\" class=\"nounderline abstract_t\">Pai AB, Pai MP. Vancomycin dosing in high flux hemodialysis: a limited-sampling algorithm. Am J Health Syst Pharm 2004; 61:1812.</a></li><li><a href=\"https://www.uptodate.com/contents/vancomycin-parenteral-dosing-monitoring-and-adverse-effects-in-adults/abstract/34\" class=\"nounderline abstract_t\">Crew P, Heintz SJ, Heintz BH. Vancomycin dosing and monitoring for patients with end-stage renal disease receiving intermittent hemodialysis. Am J Health Syst Pharm 2015; 72:1856.</a></li><li><a href=\"https://www.uptodate.com/contents/vancomycin-parenteral-dosing-monitoring-and-adverse-effects-in-adults/abstract/35\" class=\"nounderline abstract_t\">Osawa R, Kaka AS. Maculopapular rash induced by oral vancomycin. Clin Infect Dis 2008; 47:860.</a></li><li><a href=\"https://www.uptodate.com/contents/vancomycin-parenteral-dosing-monitoring-and-adverse-effects-in-adults/abstract/36\" class=\"nounderline abstract_t\">Polk RE, Israel D, Wang J, et al. Vancomycin skin tests and prediction of &quot;red man syndrome&quot; in healthy volunteers. Antimicrob Agents Chemother 1993; 37:2139.</a></li><li><a href=\"https://www.uptodate.com/contents/vancomycin-parenteral-dosing-monitoring-and-adverse-effects-in-adults/abstract/37\" class=\"nounderline abstract_t\">Appel GB, Given DB, Levine LR, Cooper GL. Vancomycin and the kidney. Am J Kidney Dis 1986; 8:75.</a></li><li><a href=\"https://www.uptodate.com/contents/vancomycin-parenteral-dosing-monitoring-and-adverse-effects-in-adults/abstract/38\" class=\"nounderline abstract_t\">Bailie GR, Neal D. Vancomycin ototoxicity and nephrotoxicity. A review. Med Toxicol Adverse Drug Exp 1988; 3:376.</a></li><li><a href=\"https://www.uptodate.com/contents/vancomycin-parenteral-dosing-monitoring-and-adverse-effects-in-adults/abstract/39\" class=\"nounderline abstract_t\">Downs NJ, Neihart RE, Dolezal JM, Hodges GR. Mild nephrotoxicity associated with vancomycin use. Arch Intern Med 1989; 149:1777.</a></li><li><a href=\"https://www.uptodate.com/contents/vancomycin-parenteral-dosing-monitoring-and-adverse-effects-in-adults/abstract/40\" class=\"nounderline abstract_t\">Rybak MJ, Albrecht LM, Boike SC, Chandrasekar PH. Nephrotoxicity of vancomycin, alone and with an aminoglycoside. J Antimicrob Chemother 1990; 25:679.</a></li><li><a href=\"https://www.uptodate.com/contents/vancomycin-parenteral-dosing-monitoring-and-adverse-effects-in-adults/abstract/41\" class=\"nounderline abstract_t\">Hidayat LK, Hsu DI, Quist R, et al. High-dose vancomycin therapy for methicillin-resistant Staphylococcus aureus infections: efficacy and toxicity. Arch Intern Med 2006; 166:2138.</a></li><li><a href=\"https://www.uptodate.com/contents/vancomycin-parenteral-dosing-monitoring-and-adverse-effects-in-adults/abstract/42\" class=\"nounderline abstract_t\">Jeffres MN, Isakow W, Doherty JA, et al. A retrospective analysis of possible renal toxicity associated with vancomycin in patients with health care-associated methicillin-resistant Staphylococcus aureus pneumonia. Clin Ther 2007; 29:1107.</a></li><li><a href=\"https://www.uptodate.com/contents/vancomycin-parenteral-dosing-monitoring-and-adverse-effects-in-adults/abstract/43\" class=\"nounderline abstract_t\">Lodise TP, Lomaestro B, Graves J, Drusano GL. Larger vancomycin doses (at least four grams per day) are associated with an increased incidence of nephrotoxicity. Antimicrob Agents Chemother 2008; 52:1330.</a></li><li><a href=\"https://www.uptodate.com/contents/vancomycin-parenteral-dosing-monitoring-and-adverse-effects-in-adults/abstract/44\" class=\"nounderline abstract_t\">Lodise TP, Patel N, Lomaestro BM, et al. Relationship between initial vancomycin concentration-time profile and nephrotoxicity among hospitalized patients. Clin Infect Dis 2009; 49:507.</a></li><li><a href=\"https://www.uptodate.com/contents/vancomycin-parenteral-dosing-monitoring-and-adverse-effects-in-adults/abstract/45\" class=\"nounderline abstract_t\">Carreno JJ, Kenney RM, Lomaestro B. Vancomycin-associated renal dysfunction: where are we now? Pharmacotherapy 2014; 34:1259.</a></li><li><a href=\"https://www.uptodate.com/contents/vancomycin-parenteral-dosing-monitoring-and-adverse-effects-in-adults/abstract/46\" class=\"nounderline abstract_t\">Rybak MJ, Abate BJ, Kang SL, et al. Prospective evaluation of the effect of an aminoglycoside dosing regimen on rates of observed nephrotoxicity and ototoxicity. Antimicrob Agents Chemother 1999; 43:1549.</a></li><li><a href=\"https://www.uptodate.com/contents/vancomycin-parenteral-dosing-monitoring-and-adverse-effects-in-adults/abstract/47\" class=\"nounderline abstract_t\">Hammond DA, Smith MN, Li C, et al. Systematic Review and Meta-Analysis of Acute Kidney Injury Associated with Concomitant Vancomycin and Piperacillin/tazobactam. Clin Infect Dis 2016.</a></li><li><a href=\"https://www.uptodate.com/contents/vancomycin-parenteral-dosing-monitoring-and-adverse-effects-in-adults/abstract/48\" class=\"nounderline abstract_t\">Navalkele B, Pogue JM, Karino S, et al. Risk of Acute Kidney Injury in Patients on Concomitant Vancomycin and Piperacillin-Tazobactam Compared to Those on Vancomycin and Cefepime. Clin Infect Dis 2017; 64:116.</a></li><li><a href=\"https://www.uptodate.com/contents/vancomycin-parenteral-dosing-monitoring-and-adverse-effects-in-adults/abstract/49\" class=\"nounderline abstract_t\">Giuliano CA, Patel CR, Kale-Pradhan PB. Is the Combination of Piperacillin-Tazobactam and Vancomycin Associated with Development of Acute Kidney Injury? A Meta-analysis. Pharmacotherapy 2016; 36:1217.</a></li><li><a href=\"https://www.uptodate.com/contents/vancomycin-parenteral-dosing-monitoring-and-adverse-effects-in-adults/abstract/50\" class=\"nounderline abstract_t\">Rutter WC, Cox JN, Martin CA, et al. Nephrotoxicity during Vancomycin Therapy in Combination with Piperacillin-Tazobactam or Cefepime. Antimicrob Agents Chemother 2017; 61.</a></li><li><a href=\"https://www.uptodate.com/contents/vancomycin-parenteral-dosing-monitoring-and-adverse-effects-in-adults/abstract/51\" class=\"nounderline abstract_t\">Burgess LD, Drew RH. Comparison of the incidence of vancomycin-induced nephrotoxicity in hospitalized patients with and without concomitant piperacillin-tazobactam. Pharmacotherapy 2014; 34:670.</a></li><li><a href=\"https://www.uptodate.com/contents/vancomycin-parenteral-dosing-monitoring-and-adverse-effects-in-adults/abstract/52\" class=\"nounderline abstract_t\">Gomes DM, Smotherman C, Birch A, et al. Comparison of acute kidney injury during treatment with vancomycin in combination with piperacillin-tazobactam or cefepime. Pharmacotherapy 2014; 34:662.</a></li><li><a href=\"https://www.uptodate.com/contents/vancomycin-parenteral-dosing-monitoring-and-adverse-effects-in-adults/abstract/53\" class=\"nounderline abstract_t\">Meaney CJ, Hynicka LM, Tsoukleris MG. Vancomycin-associated nephrotoxicity in adult medicine patients: incidence, outcomes, and risk factors. Pharmacotherapy 2014; 34:653.</a></li><li><a href=\"https://www.uptodate.com/contents/vancomycin-parenteral-dosing-monitoring-and-adverse-effects-in-adults/abstract/54\" class=\"nounderline abstract_t\">Hammond DA, Smith MN, Painter JT, et al. Comparative Incidence of Acute Kidney Injury in Critically Ill Patients Receiving Vancomycin with Concomitant Piperacillin-Tazobactam or Cefepime: A Retrospective Cohort Study. Pharmacotherapy 2016; 36:463.</a></li><li><a href=\"https://www.uptodate.com/contents/vancomycin-parenteral-dosing-monitoring-and-adverse-effects-in-adults/abstract/55\" class=\"nounderline abstract_t\">Karino S, Kaye KS, Navalkele B, et al. Epidemiology of Acute Kidney Injury among Patients Receiving Concomitant Vancomycin and Piperacillin-Tazobactam: Opportunities for Antimicrobial Stewardship. Antimicrob Agents Chemother 2016; 60:3743.</a></li><li><a href=\"https://www.uptodate.com/contents/vancomycin-parenteral-dosing-monitoring-and-adverse-effects-in-adults/abstract/56\" class=\"nounderline abstract_t\">Rutter WC, Burgess DR, Talbert JC, Burgess DS. Acute kidney injury in patients treated with vancomycin and piperacillin-tazobactam: A retrospective cohort analysis. J Hosp Med 2017; 12:77.</a></li><li><a href=\"https://www.uptodate.com/contents/vancomycin-parenteral-dosing-monitoring-and-adverse-effects-in-adults/abstract/57\" class=\"nounderline abstract_t\">Downes KJ, Cowden C, Laskin BL, et al. Association of Acute Kidney Injury With Concomitant Vancomycin and Piperacillin/Tazobactam Treatment Among Hospitalized Children. JAMA Pediatr 2017; 171:e173219.</a></li><li><a href=\"https://www.uptodate.com/contents/vancomycin-parenteral-dosing-monitoring-and-adverse-effects-in-adults/abstract/58\" class=\"nounderline abstract_t\">Mousavi M, Zapolskaya T, Scipione MR, et al. Comparison of Rates of Nephrotoxicity Associated with Vancomycin in Combination with Piperacillin-Tazobactam Administered as an Extended versus Standard Infusion. Pharmacotherapy 2017; 37:379.</a></li><li><a href=\"https://www.uptodate.com/contents/vancomycin-parenteral-dosing-monitoring-and-adverse-effects-in-adults/abstract/59\" class=\"nounderline abstract_t\">Klibanov OM, Filicko JE, DeSimone JA Jr, Tice DS. Sensorineural hearing loss associated with intrathecal vancomycin. Ann Pharmacother 2003; 37:61.</a></li><li><a href=\"https://www.uptodate.com/contents/vancomycin-parenteral-dosing-monitoring-and-adverse-effects-in-adults/abstract/60\" class=\"nounderline abstract_t\">Forouzesh A, Moise PA, Sakoulas G. Vancomycin ototoxicity: a reevaluation in an era of increasing doses. Antimicrob Agents Chemother 2009; 53:483.</a></li><li><a href=\"https://www.uptodate.com/contents/vancomycin-parenteral-dosing-monitoring-and-adverse-effects-in-adults/abstract/61\" class=\"nounderline abstract_t\">Brummett RE. Ototoxicity of vancomycin and analogues. Otolaryngol Clin North Am 1993; 26:821.</a></li><li><a href=\"https://www.uptodate.com/contents/vancomycin-parenteral-dosing-monitoring-and-adverse-effects-in-adults/abstract/62\" class=\"nounderline abstract_t\">Brummett RE, Fox KE, Jacobs F, et al. Augmented gentamicin ototoxicity induced by vancomycin in guinea pigs. Arch Otolaryngol Head Neck Surg 1990; 116:61.</a></li><li><a href=\"https://www.uptodate.com/contents/vancomycin-parenteral-dosing-monitoring-and-adverse-effects-in-adults/abstract/63\" class=\"nounderline abstract_t\">de Hoog M, van Zanten BA, Hop WC, et al. Newborn hearing screening: tobramycin and vancomycin are not risk factors for hearing loss. J Pediatr 2003; 142:41.</a></li><li><a href=\"https://www.uptodate.com/contents/vancomycin-parenteral-dosing-monitoring-and-adverse-effects-in-adults/abstract/64\" class=\"nounderline abstract_t\">Rodvold KA, Blum RA, Fischer JH, et al. Vancomycin pharmacokinetics in patients with various degrees of renal function. Antimicrob Agents Chemother 1988; 32:848.</a></li><li><a href=\"https://www.uptodate.com/contents/vancomycin-parenteral-dosing-monitoring-and-adverse-effects-in-adults/abstract/65\" class=\"nounderline abstract_t\">Skhirtladze K, Hutschala D, Fleck T, et al. Impaired target site penetration of vancomycin in diabetic patients following cardiac surgery. Antimicrob Agents Chemother 2006; 50:1372.</a></li><li><a href=\"https://www.uptodate.com/contents/vancomycin-parenteral-dosing-monitoring-and-adverse-effects-in-adults/abstract/66\" class=\"nounderline abstract_t\">Cruciani M, Gatti G, Lazzarini L, et al. Penetration of vancomycin into human lung tissue. J Antimicrob Chemother 1996; 38:865.</a></li><li><a href=\"https://www.uptodate.com/contents/vancomycin-parenteral-dosing-monitoring-and-adverse-effects-in-adults/abstract/67\" class=\"nounderline abstract_t\">Lin Wu FL, Liu SS, Yang TY, et al. A Larger Dose of Vancomycin Is Required in Adult Neurosurgical Intensive Care Unit Patients Due to Augmented Clearance. Ther Drug Monit 2015; 37:609.</a></li><li><a href=\"https://www.uptodate.com/contents/vancomycin-parenteral-dosing-monitoring-and-adverse-effects-in-adults/abstract/68\" class=\"nounderline abstract_t\">Moise-Broder PA, Forrest A, Birmingham MC, Schentag JJ. Pharmacodynamics of vancomycin and other antimicrobials in patients with Staphylococcus aureus lower respiratory tract infections. Clin Pharmacokinet 2004; 43:925.</a></li><li><a href=\"https://www.uptodate.com/contents/vancomycin-parenteral-dosing-monitoring-and-adverse-effects-in-adults/abstract/69\" class=\"nounderline abstract_t\">Casapao AM, Lodise TP, Davis SL, et al. Association between vancomycin day 1 exposure profile and outcomes among patients with methicillin-resistant Staphylococcus aureus infective endocarditis. Antimicrob Agents Chemother 2015; 59:2978.</a></li><li><a href=\"https://www.uptodate.com/contents/vancomycin-parenteral-dosing-monitoring-and-adverse-effects-in-adults/abstract/70\" class=\"nounderline abstract_t\">Song KH, Kim HB, Kim HS, et al. Impact of area under the concentration-time curve to minimum inhibitory concentration ratio on vancomycin treatment outcomes in methicillin-resistant Staphylococcus aureus bacteraemia. Int J Antimicrob Agents 2015; 46:689.</a></li><li><a href=\"https://www.uptodate.com/contents/vancomycin-parenteral-dosing-monitoring-and-adverse-effects-in-adults/abstract/71\" class=\"nounderline abstract_t\">Rybak MJ. The pharmacokinetic and pharmacodynamic properties of vancomycin. Clin Infect Dis 2006; 42 Suppl 1:S35.</a></li><li><a href=\"https://www.uptodate.com/contents/vancomycin-parenteral-dosing-monitoring-and-adverse-effects-in-adults/abstract/72\" class=\"nounderline abstract_t\">Lodise TP, Drusano GL, Zasowski E, et al. Vancomycin exposure in patients with methicillin-resistant Staphylococcus aureus bloodstream infections: how much is enough? Clin Infect Dis 2014; 59:666.</a></li><li><a href=\"https://www.uptodate.com/contents/vancomycin-parenteral-dosing-monitoring-and-adverse-effects-in-adults/abstract/73\" class=\"nounderline abstract_t\">Kullar R, Davis SL, Levine DP, Rybak MJ. Impact of vancomycin exposure on outcomes in patients with methicillin-resistant Staphylococcus aureus bacteremia: support for consensus guidelines suggested targets. Clin Infect Dis 2011; 52:975.</a></li><li><a href=\"https://www.uptodate.com/contents/vancomycin-parenteral-dosing-monitoring-and-adverse-effects-in-adults/abstract/74\" class=\"nounderline abstract_t\">Jeffres MN, Isakow W, Doherty JA, et al. Predictors of mortality for methicillin-resistant Staphylococcus aureus health-care-associated pneumonia: specific evaluation of vancomycin pharmacokinetic indices. Chest 2006; 130:947.</a></li><li><a href=\"https://www.uptodate.com/contents/vancomycin-parenteral-dosing-monitoring-and-adverse-effects-in-adults/abstract/75\" class=\"nounderline abstract_t\">Pai MP, Neely M, Rodvold KA, Lodise TP. Innovative approaches to optimizing the delivery of vancomycin in individual patients. Adv Drug Deliv Rev 2014; 77:50.</a></li><li><a href=\"https://www.uptodate.com/contents/vancomycin-parenteral-dosing-monitoring-and-adverse-effects-in-adults/abstract/76\" class=\"nounderline abstract_t\">Steinmetz T, Eliakim-Raz N, Goldberg E, et al. Association of vancomycin serum concentrations with efficacy in patients with MRSA infections: a systematic review and meta-analysis. Clin Microbiol Infect 2015; 21:665.</a></li><li><a href=\"https://www.uptodate.com/contents/vancomycin-parenteral-dosing-monitoring-and-adverse-effects-in-adults/abstract/77\" class=\"nounderline abstract_t\">Prybylski JP. Vancomycin Trough Concentration as a Predictor of Clinical Outcomes in Patients with Staphylococcus aureus Bacteremia: A Meta-analysis of Observational Studies. Pharmacotherapy 2015; 35:889.</a></li><li><a href=\"https://www.uptodate.com/contents/vancomycin-parenteral-dosing-monitoring-and-adverse-effects-in-adults/abstract/78\" class=\"nounderline abstract_t\">Patel N, Pai MP, Rodvold KA, et al. Vancomycin: we can't get there from here. Clin Infect Dis 2011; 52:969.</a></li><li><a href=\"https://www.uptodate.com/contents/vancomycin-parenteral-dosing-monitoring-and-adverse-effects-in-adults/abstract/79\" class=\"nounderline abstract_t\">Haeseker M, Croes S, Neef C, et al. Evaluation of Vancomycin Prediction Methods Based on Estimated Creatinine Clearance or Trough Levels. Ther Drug Monit 2016; 38:120.</a></li><li><a href=\"https://www.uptodate.com/contents/vancomycin-parenteral-dosing-monitoring-and-adverse-effects-in-adults/abstract/80\" class=\"nounderline abstract_t\">Moise PA, Sakoulas G, Forrest A, Schentag JJ. Vancomycin in vitro bactericidal activity and its relationship to efficacy in clearance of methicillin-resistant Staphylococcus aureus bacteremia. Antimicrob Agents Chemother 2007; 51:2582.</a></li><li><a href=\"https://www.uptodate.com/contents/vancomycin-parenteral-dosing-monitoring-and-adverse-effects-in-adults/abstract/81\" class=\"nounderline abstract_t\">Sakoulas G, Moise-Broder PA, Schentag J, et al. Relationship of MIC and bactericidal activity to efficacy of vancomycin for treatment of methicillin-resistant Staphylococcus aureus bacteremia. J Clin Microbiol 2004; 42:2398.</a></li><li><a href=\"https://www.uptodate.com/contents/vancomycin-parenteral-dosing-monitoring-and-adverse-effects-in-adults/abstract/82\" class=\"nounderline abstract_t\">Lodise TP, Graves J, Evans A, et al. Relationship between vancomycin MIC and failure among patients with methicillin-resistant Staphylococcus aureus bacteremia treated with vancomycin. Antimicrob Agents Chemother 2008; 52:3315.</a></li><li><a href=\"https://www.uptodate.com/contents/vancomycin-parenteral-dosing-monitoring-and-adverse-effects-in-adults/abstract/83\" class=\"nounderline abstract_t\">Sakoulas G, Gold HS, Cohen RA, et al. Effects of prolonged vancomycin administration on methicillin-resistant Staphylococcus aureus (MRSA) in a patient with recurrent bacteraemia. J Antimicrob Chemother 2006; 57:699.</a></li></ol></div><div id=\"topicVersionRevision\">Topic 484 Version 36.0</div></div>","outline":"<div id=\"outlineSections\"><h2>Topic Outline</h2><ul id=\"innerOutline\"><li class=\"sr-button\"><a href=\"#H22\"><span>SUMMARY</span></a></li><li><a href=\"#H1\" id=\"outline-link-H1\">INTRODUCTION</a></li><li><a href=\"#H3529742722\" id=\"outline-link-H3529742722\">DOSING AND ADMINISTRATION</a><ul><li><a href=\"#H8\" id=\"outline-link-H8\">Clinical approach</a></li><li><a href=\"#H3269410249\" id=\"outline-link-H3269410249\">General principles</a><ul><li><a href=\"#H1922449566\" id=\"outline-link-H1922449566\">- Approach to infusion</a></li><li><a href=\"#H3722373455\" id=\"outline-link-H3722373455\">- Loading dose</a></li><li><a href=\"#H1884293851\" id=\"outline-link-H1884293851\">- Serum concentration monitoring</a><ul><li><a href=\"#H3053721516\" id=\"outline-link-H3053721516\">Target concentrations</a></li><li><a href=\"#H1455059606\" id=\"outline-link-H1455059606\">Dose adjustments</a></li></ul></li><li><a href=\"#H10\" id=\"outline-link-H10\">- Obese patients</a></li><li><a href=\"#H3345648004\" id=\"outline-link-H3345648004\">- Patients on renal replacement therapy</a><ul><li><a href=\"#H21\" id=\"outline-link-H21\">Hemodialysis</a></li><li><a href=\"#H419376098\" id=\"outline-link-H419376098\">Peritoneal dialysis</a></li><li><a href=\"#H1187413911\" id=\"outline-link-H1187413911\">Continuous renal replacement</a></li></ul></li></ul></li></ul></li><li><a href=\"#H1269346913\" id=\"outline-link-H1269346913\">ADVERSE EFFECTS</a><ul><li><a href=\"#H902800417\" id=\"outline-link-H902800417\">Red man syndrome</a></li><li><a href=\"#H3209587989\" id=\"outline-link-H3209587989\">Nephrotoxicity</a></li><li><a href=\"#H2072386946\" id=\"outline-link-H2072386946\">Ototoxicity</a></li></ul></li><li><a href=\"#H536241036\" id=\"outline-link-H536241036\">PHARMACOKINETICS AND PHARMACODYNAMICS</a></li><li><a href=\"#H22\" id=\"outline-link-H22\">SUMMARY</a></li><li><a href=\"#references\">REFERENCES</a></li></ul></div><div><h2>GRAPHICS <a href=\"#\" id=\"viewAllGraphicsLink\">View All</a></h2><div id=\"outlineGraphics\"><ul><li><div id=\"ID/484|TAB\" class=\"openRelatedGraphics\"><a href=\"#\" title=\"TABLES\">TABLES</a></div><ul><li><a href=\"image.htm?imageKey=ID/60466\" class=\"graphic graphic_table\">- Vancomycin dosing in adults not receiving HD</a></li><li><a href=\"image.htm?imageKey=ID/97965\" class=\"graphic graphic_table\">- Vancomycin dose in patients with high-flux HD</a></li></ul></li></ul></div></div><div><h2>CALCULATORS</h2><div id=\"outlineCalculators\"><ul><li class=\"plainItem\"><a href=\"topic.htm?path=calculator-creatinine-clearance-estimate-by-cockcroft-gault-equation-in-adults-and-older-adolescents-age-18-years\" title=\"calculator 1\" class=\"calc calc_professional\">Calculator: Creatinine clearance estimate by Cockcroft-Gault equation in adults and older adolescents (age &ge;18 years)</a></li><li class=\"plainItem\"><a href=\"topic.htm?path=calculator-body-mass-index-bmi-quetelets-index-in-adults\" title=\"calculator 2\" class=\"calc calc_professional\">Calculator: Body mass index (BMI; Quetelet's index) in adults</a></li><li class=\"plainItem\"><a href=\"topic.htm?path=calculator-ideal-body-weight-method-of-devine-and-dosing-weight-for-adults\" title=\"calculator 3\" class=\"calc calc_professional\">Calculator: Ideal body weight (method of Devine) and dosing weight for adults</a></li><li class=\"plainItem\"><a href=\"topic.htm?path=calculator-lean-body-weight-adult-male\" title=\"calculator 4\" class=\"calc calc_professional\">Calculator: Lean body weight (adult male)</a></li><li class=\"plainItem\"><a href=\"topic.htm?path=calculator-lean-body-weight-adult-female\" title=\"calculator 5\" class=\"calc calc_professional\">Calculator: Lean body weight (adult female)</a></li></ul></div></div><div><h2>RELATED TOPICS</h2><div id=\"outlineTopics\"><ul><li class=\"plainItem\"><a href=\"topic.htm?path=assessment-of-kidney-function\" class=\"medical medical_review\">Assessment of kidney function</a></li><li class=\"plainItem\"><a href=\"topic.htm?path=methicillin-resistant-staphylococcus-aureus-mrsa-in-adults-treatment-of-bacteremia\" class=\"medical medical_review\">Methicillin-resistant Staphylococcus aureus (MRSA) in adults: Treatment of bacteremia</a></li><li class=\"plainItem\"><a href=\"topic.htm?path=microbiology-and-therapy-of-peritonitis-in-peritoneal-dialysis\" class=\"medical medical_review\">Microbiology and therapy of peritonitis in peritoneal dialysis</a></li><li class=\"plainItem\"><a href=\"topic.htm?path=overview-of-antibacterial-susceptibility-testing\" class=\"medical medical_review\">Overview of antibacterial susceptibility testing</a></li><li class=\"plainItem\"><a href=\"topic.htm?path=vancomycin-hypersensitivity\" class=\"medical medical_review\">Vancomycin hypersensitivity</a></li></ul></div></div>","javascript":null}